Education
About Us
Working with TipRanks
Follow Us
Immunitybio Inc (DE:26CA)
NASDAQ:26CA
26CA Stock Chart & Stats
€8.92
-€0.11(-4.34%)
At close: 4:00 PM EST
€8.92
-€0.11(-4.34%)
Day’s Range― - ―
52-Week Range€1.63 - €10.40
Previous CloseN/A
Volume0.00
Average Volume (3M)8.41K
Market Cap
€9.18B
Enterprise Value€10.63B
Total Cash (Recent Filing)€242.82M
Total Debt (Recent Filing)€878.12M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 07, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding1,028,111,500
10 Day Avg. Volume8,581
30 Day Avg. Volume8,410
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.55Price Target Upside-4.11% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.25
Revenue Forecast (FY)€177.81M
Bulls Say, Bears Say
Bulls Say
Clinical Mechanism And Platform PotentialData showing lymphocyte restoration associated with longer survival across tumor types supports ANKTIVA's potential as a combinable immunotherapy backbone beyond bladder cancer.
Commercial TractionRapid uptake after the U.S. launch and rising unit volumes indicate accelerating physician adoption and support revenue growth as ANKTIVA moves toward an established commercial franchise.
Regulatory ApprovalEuropean conditional marketing authorization for ANKTIVA plus BCG establishes broader regulatory validation and meaningfully expands the therapy's commercial runway across multiple jurisdictions.
Bears Say
Clinical Validation RiskQuestions about the durability and functional quality of restored lymphocytes and whether regulators will accept lymphocyte counts as a meaningful endpoint raise the risk that immune restoration may not secure broader label expansions.
Regulatory ObligationsConditional authorization and required post‑marketing commitments create uncertainty around the timing and scope of confirmatory data submissions, posing regulatory and commercial risk.
Reimbursement And Market AccessUncertainty about national reimbursement decisions in Europe could limit initial market penetration and temper commercial forecasts for ANKTIVA.
ImmunityBio News
26CA FAQ
What was Immunitybio Inc’s price range in the past 12 months?
Immunitybio Inc lowest stock price was €1.63 and its highest was €10.40 in the past 12 months.
What is Immunitybio Inc’s market cap?
Immunitybio Inc’s market cap is €9.18B.
When is Immunitybio Inc’s upcoming earnings report date?
Immunitybio Inc’s upcoming earnings report date is May 07, 2026 which is in 64 days.
How were Immunitybio Inc’s earnings last quarter?
Immunitybio Inc released its earnings results on Mar 03, 2026. The company reported -€0.051 earnings per share for the quarter, beating the consensus estimate of -€0.066 by €0.015.
Is Immunitybio Inc overvalued?
According to Wall Street analysts Immunitybio Inc’s price is currently Overvalued.
Does Immunitybio Inc pay dividends?
Immunitybio Inc does not currently pay dividends.
What is Immunitybio Inc’s EPS estimate?
Immunitybio Inc’s EPS estimate is -0.07.
How many shares outstanding does Immunitybio Inc have?
Immunitybio Inc has 1,028,111,500 shares outstanding.
What happened to Immunitybio Inc’s price movement after its last earnings report?
Immunitybio Inc reported an EPS of -€0.051 in its last earnings report, beating expectations of -€0.066. Following the earnings report the stock price went down -8.163%.
Which hedge fund is a major shareholder of Immunitybio Inc?
Currently, no hedge funds are holding shares in DE:26CA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.55 (-4.11% Downside)
€8.55 (-4.11% Downside)
Blogger Sentiment
Bullish
DE:26CA Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.07%
Trailing 12-Months
Company Description
Immunitybio Inc
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
26CA Earnings Call
Q4 2026
0:00 / 0:00
26CA Stock 12 Month Forecast
Average Price Target
€8.55
▼(-4.11% Downside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Options Prices
Currently, No data available
---